updated results of a clinical trial evaluating pembrolizumab axitinib for frontline adv rcc
Published 4 years ago • 69 plays • Length 8:50Download video MP4
Download video MP3
Similar videos
-
3:26
extended follow-up from a trial of pembrolizumab plus axitinib for advanced renal cell carcinoma
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
4:17
longer term outcomes with pembrolizumab plus axitinib for advanced rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:29
phase i/ii study of nivolumab and axitinib for advanced rcc
-
3:29
what is the most exciting ongoing clinical trial in rcc?
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
6:58
keynote-426 study
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
0:44
real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc